Last Update 10 Mar 26

Fair value Decreased 41%

TBPH: Cost Reset And Cash Runway Will Support Future Upside Potential

Analysts have cut their average price target on Theravance Biopharma from about $26.71 to roughly $15.83 after the ampreloxetine Phase 3 CYPRESS study miss. Revised models place more weight on existing respiratory assets, cost reductions, and the current cash position.

Analyst Commentary

Recent research updates show a split view on Theravance Biopharma after the CYPRESS outcome, with some analysts focusing on remaining respiratory assets and cash, and others highlighting reduced upside after removing ampreloxetine from their models.

Bullish Takeaways

Bullish analysts point to valuation support from Yupelri and residual Trelegy rights as key pillars for the equity story now that ampreloxetine is removed from several models.
Some models still carry Buy ratings alongside reduced price targets in the mid-teens to low twenties, which these analysts describe as leaving room for execution on the existing portfolio to support current valuations.
Planned reductions in R&D and G&A, with a stated goal of about US$70m in cost savings versus 2025 OpEx, are described as a way to tighten the cost base and potentially improve the durability of the current cash position.
The reported US$326.5m cash balance is cited as providing runway through the company’s reset period, which bullish analysts say gives management time to focus on monetizing Yupelri, Trelegy payments, and China royalties.

Bearish Takeaways

Bearish analysts emphasize the removal of ampreloxetine from their models, which cuts a previous source of optionality and reduces perceived upside drivers for the stock.
Some have moved ratings to more neutral stances and lowered price targets into the mid-teens. These changes reflect a view that the equity is now more tightly linked to existing respiratory assets with limited pipeline diversification.
The failure of the CYPRESS study to meet its primary endpoint and the plan to wind down the program are described as weakening the growth narrative that had been tied to ampreloxetine’s potential.
Comments about limited visibility into new upside catalysts indicate concerns around execution on future R&D and business development. There is caution that additional analyses on ampreloxetine do not currently translate into a clear path forward.

What's in the News

Theravance Biopharma plans a restructuring expected to affect about 50% of its workforce, including a full wind down of the R&D organization and a roughly 50% reduction in G&A staff, with estimated one time cash severance costs of US$5 million to US$7 million (Key Developments).
Topline Phase 3 CYPRESS results showed ampreloxetine did not meet the primary endpoint on the OHSA composite score in symptomatic nOH due to MSA, and the company plans to wind down the ampreloxetine program (Key Developments).
The Board’s Strategic Review Committee, working with Lazard, is accelerating its ongoing review of alternatives that include a possible sale of the company, while stating there is no assurance that this process will lead to any transaction (Key Developments).
Theravance Biopharma is implementing a cost focused restructuring around YUPELRI. It is targeting about a 60% reduction in operating expenses compared with 2025 preliminary actuals of roughly US$110 million, and about US$70 million of run rate cost savings that are expected to be fully reflected in third quarter 2026 (Key Developments).
The company identifies its main sources of value as roughly US$400 million of expected cash at the end of first quarter 2026, a 35% interest in YUPELRI, a potential US$100 million TRELEGY milestone, and Irish tax attributes. It is also completing additional analyses of the CYPRESS dataset to assess any remaining value in ampreloxetine (Key Developments).

Valuation Changes

Fair Value: Consensus fair value estimate moved from about $26.71 to roughly $15.83 per share, a reduction of around 40%.
Discount Rate: Analyst models keep the discount rate essentially unchanged at about 6.98%, which suggests the required return assumption is stable.
Revenue Growth: Long term annual revenue growth assumption shifted from roughly 23.28% to about 4.78%, a very large cut that places more weight on a slower growth profile.
Net Profit Margin: Expected net profit margin increased from about 5.24% to roughly 34.82%, which indicates a stronger focus on cost cuts and a leaner operating model in forecasts.
Future P/E: Forward P/E assumption moved from about 215.62x to around 31.33x, a very large compression in the multiple analysts apply to future earnings.

0 views

Key Takeaways

Sustained demand for key therapies and new product approvals support revenue growth, expanded margins, and enhanced operating leverage in both established and emerging markets.
Streamlined cost structure, controlled spending, and a robust cash position reduce financial risk while enabling reinvestment in pipeline assets and supporting future earnings growth.
Heavy reliance on a few products, reduced royalty streams, tough pricing pressures, and rising competition create significant risks to growth, margins, and revenue stability.

Catalysts

About Theravance Biopharma

A biopharmaceutical company, develops and commercializes of medicines in the United States.What are the underlying business or industry changes driving this perspective?

The advancing aging global population and rising prevalence of chronic diseases continue to drive increased demand for chronic and respiratory treatments, supporting YUPELRI's sustained double-digit sales growth and expanded profit margins, which are likely to have a positive impact on revenue and operating leverage.
The near-term potential for ampreloxetine, a precision medicine therapy in a rare neurogenic condition (MSA with nOH) with high unmet need and a targeted addressable US population, positions Theravance to capture outsized revenue and enjoy favorable pricing dynamics versus historical benchmarks, with significant implications for future top-line growth and net margins if successful.
Newly achieved YUPELRI approval in China, with the commercial launch being managed by Viatris at no incremental cost to Theravance, offers access to a large, expanding emerging-market customer base, creating forward-looking upside in royalty income and milestone payments without margin dilution from increased SG&A.
A streamlined, focused cost structure after recent restructuring, combined with disciplined R&D and SG&A spending (including stable prelaunch expenses and targeted future investments), is positioned to enhance operating margins and support improved earnings leverage as commercial and pipeline assets mature.
Strong cash position, expected near-term milestone inflows (up to $175 million from TRELEGY and YUPELRI), and profitable, recurring revenue streams reduce financial risk and enable reinvestment in growth opportunities or return of excess capital to shareholders, directly supporting net income stability and potential for future EPS expansion.

Theravance Biopharma Earnings and Revenue Growth

Theravance Biopharma Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Theravance Biopharma's revenue will grow by 18.6% annually over the next 3 years.
Analysts are not forecasting that Theravance Biopharma will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Theravance Biopharma's profit margin will increase from 16.9% to the average US Pharmaceuticals industry of 23.2% in 3 years.
If Theravance Biopharma's profit margin were to converge on the industry average, you could expect earnings to reach $29.9 million (and earnings per share of $0.55) by about September 2028, up from $13.0 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $62.6 million in earnings, and the most bearish expecting $-48 million.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 40.4x on those 2028 earnings, down from 53.1x today. This future PE is greater than the current PE for the US Pharmaceuticals industry at 19.5x.
Analysts expect the number of shares outstanding to grow by 2.41% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 6.78%, as per the Simply Wall St company report.

Theravance Biopharma Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

Theravance's revenue base remains highly concentrated: Aside from YUPELRI, much of its near-term value depends on successful approval and commercialization of ampreloxetine, leaving the company vulnerable to negative trial outcomes or underperformance of one key asset; revenue and earnings could become volatile if ampreloxetine fails to deliver as expected.
The company has divested its only substantial external royalty stream by selling its remaining interest in TRELEGY, meaning future cash inflows will depend more heavily on internal assets and milestone payments; longer term, this reduces recurring revenue diversification and heightens exposure to product-specific risks, impacting revenue stability and net margins.
The pricing and reimbursement environment for new rare disease drugs is increasingly challenging, with growing payer pushback in the U.S. and heightened scrutiny on value-based pricing-especially as ampreloxetine's price may benchmark against high-cost alternatives; this threatens expected revenue growth and margin realization even upon regulatory approval.
YUPELRI's future growth faces potential headwinds from increasing competition in the respiratory care market from both large pharmaceutical companies and generics (especially after patent expiry, despite protection to 2039), putting continued market share, pricing, and profitability at long-term risk.
Operating leverage and margin improvement appear dependent on keeping costs flat while scaling sales, but any failure to achieve ambitious sales targets, encounter larger-than-expected SG&A increases (post-ampreloxetine launch), or delays/shortcomings in the launch or market uptake of new therapies could erode anticipated profit margins and cash flow.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $18.4 for Theravance Biopharma based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $26.0, and the most bearish reporting a price target of just $13.0.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $128.8 million, earnings will come to $29.9 million, and it would be trading on a PE ratio of 40.4x, assuming you use a discount rate of 6.8%.
Given the current share price of $13.74, the analyst price target of $18.4 is 25.4% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Theravance Biopharma?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Chronic And Respiratory Care Will Fuel Future Market Expansion